External broker reports(aggregated public sources), CMB International

CMB International

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

External broker reports(aggregated public sources)

Equity Bottom-Up

CSPC Pharmaceutical Group / Equity Bottom-Up

<ul><li>CSPC reported FY22 revenue of RMB30.94bn (+11.0% YoY) and attributable net profit of RMB6.09bn (+8.7% YoY), in line with our estimates of RMB31.35bn revenue and RMB5.99bn net profit, respectively.</li><li>The FY22 sales of finished drugs increased +8.1% YoY to RMB22.68bn, mainly driven by the steady sales performance of nervous system disease drugs and strong growth of anti-infective drugs.</li><li>Bulk product sales delivered +23.8% YoY growth to RMB6.42bn in FY22, thanks to the increase of functional food &amp; other business (+43.9% YoY) driven by the growth of caffeine products in both sales volume and average selling price.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

CSPC reported FY22 revenue of RMB30.94bn (+11.0% YoY) and attributable net profit of RMB6.09bn (+8.7% YoY), in line with our estimates of RMB31.35bn revenue and RMB5.99bn net profit, respectively.The FY22 sales of finished drugs increased +8.1% YoY to RMB22.68bn, mainly driven by the steady sales performance of nervous system disease drugs and strong growth of anti-infective drugs.Bulk product sales delivered +23.8% YoY growth to RMB6.42bn in FY22, thanks to the increase of functional food &amp; other business (+43.9% YoY) driven by the growth of caffeine products in both sales volume and average selling price.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

CSPC Pharmaceutical (1093 HK) – mRNA platform verified with product approval